Axsome Therapeutics is expected to report Q2 2026 revenue of $221.11 million and a consensus loss of $0.99 per share, with the stock currently trading at $213.99 against an average analyst target of $258.69.
Investors are primarily focused on the commercial ramp of Auvelity following its June 2026 launch for Alzheimer’s disease agitation (ADA), a milestone expected to significantly expand the drug's total addressable market.
Management recently raised Auvelity's peak sales projection to $8 billion, split between the depression and ADA indications. Performance this quarter is seen as a vital test of Axsome's commercial execution and its progress toward cash-flow positivity.